This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 2 of 28 for:    dupilumab

Dupilumab Compassionate Use Study

Expanded access is currently available for this treatment.
Verified June 2017 by Sally E. Wenzel MD, University of Pittsburgh
Information provided by (Responsible Party):
Sally E. Wenzel MD, University of Pittsburgh Identifier:
First received: January 11, 2017
Last updated: June 26, 2017
Last verified: June 2017
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.

Condition Intervention
Asthma Drug: Dupilumab

Study Type: Expanded Access     What is Expanded Access?
Official Title: Dupilumab Compassionate Use Study

Resource links provided by NLM:

Further study details as provided by Sally E. Wenzel MD, University of Pittsburgh:

Intervention Details:
    Drug: Dupilumab
    The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
Detailed Description:

This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy.

The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Sever systemic corticosteroid dependent asthma for more than 5 years

Exclusion Criteria:

  • Disease other than asthma
  • Circulation eosinophils more than 1500/ul
  • Current smoker or more than 10 pack years

This is a single-patient study. The University of Pittsburgh site is not enrolling new patients.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03020810

Contact: Catherine Vitari, RN BSN AE-C 4126479955

Sponsors and Collaborators
Sally E. Wenzel MD
  More Information

Responsible Party: Sally E. Wenzel MD, Professor of Medicine, University of Pittsburgh Identifier: NCT03020810     History of Changes
Other Study ID Numbers: PRO16120334
Study First Received: January 11, 2017
Last Updated: June 26, 2017 processed this record on September 25, 2017